Investigational Antibody GBR 1342 Receives Orphan Drug Designation for Multiple Myeloma — Myeloma Research News

GBR 1342, an investigational bispecific antibody developed by Glenmark Pharmaceuticals, was granted orphan drug designation by the U.S Food and Drug Administration (FDA) for the treatment of multiple myeloma patients who have received prior therapies. The FDA’s Office of Orphan Products Development (OOPD) gives this designation to novel therapies intended to improve the treatment and management…

Investigational Antibody GBR 1342 Receives Orphan Drug Designation for Multiple Myeloma — Myeloma Research News

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.